EFTX-G12V-pTEAD / EnFuego Therapeutics - LARVOL DELTA

Synergistic co-targeting of KRAS G12V and pan-TEAD by an EGFR-directed, inverted chimeric RNAi molecule (AACR 2026) - "Using this siRNA and EFTX-G12V we developed EFTX-G12V-pTEAD, that inhibits KRAS G12V, TEAD1-4 and downstream signaling at both the mRNA and the protein level. Using spatial profiling in the kidney, we found that our siRNA molecules do not enter podocytes and largely clear through the proximal tubules, therefore we anticipate the potential for less kidney toxicity and a wider therapeutic window using this therapeutic modality. Together our findings represent a technological advance in multi-oncogene targeting using RNAi and a therapeutic modality capable of addressing resistance to KRAS inhibitors."

Oncology • Pancreatic Cancer • Solid Tumor • EGFR • KRAS • TEAD1